Price
CHART BY
Frequently asked questions
What is Boston's market capitalization?
The market capitalization of Boston is $131.10B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Boston's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Boston is 73.57. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Boston?
Boston's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.209. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Boston's stock?
Currently, 35 analysts cover Boston's stock, with a consensus target price of $100.96. Analyst ratings provide insights into the stock's expected performance.
What is Boston's revenue over the trailing twelve months?
Over the trailing twelve months, Boston reported a revenue of $15.91B.
What is the EBITDA for Boston?
Boston's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $3.86B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Boston?
Boston has a free cash flow of $2.16B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Boston have, and what sector and industry does it belong to?
Boston employs approximately 48,000 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Boston's shares?
The free float of Boston is 1.47B. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $131.10B
- EPS (TTM)
- $1.209
- Free Float
- 1.47B
- P/E ratio (TTM)
- 73.57
- Revenue (TTM)
- $15.91B
- EBITDA (TTM)
- $3.86B
- Free Cashflow (TTM)
- $2.16B
Pricing
- 1D span
- $87.47$89.58
- 52W span
- $55.69$91.87
Analyst Ratings
The price target is $100.96 and the stock is covered by 35 analysts.
Buy
29
Hold
6
Sell
0
Information
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
- Employees
- 48,000
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US1011371077
- Primary Ticker
- BSX